Annual report [Section 13 and 15(d), not S-K Item 405]

Share-Based Compensation - Summary of Activities Under Share-Based Compensation Plans (Detail)

v3.25.4
Share-Based Compensation - Summary of Activities Under Share-Based Compensation Plans (Detail) - USD ($)
$ / shares in Units, shares in Thousands, $ in Millions
 12 Months Ended
Dec. 31, 2025
Dec. 31, 2024
Dec. 31, 2023
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]      
Outstanding and nonvested as of December 31, 2024, Number of Shares 6,289    
Granted, Number of Shares [1] 1,817    
Vested, Number of Shares (3,037)    
Forfeited, Number of Shares (503)    
Outstanding and nonvested as of December 31, 2025, Shares 4,566 [1] 6,289  
Number of Shares, Expected to vest, Ending Balance [2] 4,134    
Outstanding and nonvested as of December 31, 2024, Weighted Average Grant Date Fair Value Per Share $ 12.56    
Granted, Weighted Average Grant Date Fair Value Per Share [1] 8.13    
Vested, Weighted Average Grant Date Fair Value Per Share 14.54    
Forfeited, Weighted Average Grant Date Fair Value Per Share 10.78    
Outstanding and nonvested as of December 31, 2025, Weighted Average Grant Date Fair Value Per Share 9.67 [1] $ 12.56  
Expected to vest as of December 31, 2025, Weighted Average Grant Date Fair Value Per Share [2] $ 9.79    
Stock Appreciation Rights (SARs)      
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]      
Number of Awards Outstanding, Beginning Balance [3] 11,002    
Granted, Number of Awards [4] 2,723    
Forfeited/expired, Number of Awards [5] (476)    
Number of Awards Outstanding, Ending Balance [3] 13,249 11,002  
Number of Awards Exercisable, Ending Balance [6] 5,119    
Number of Awards Vested and expected to vest, Ending Balance [6] 9,700    
Weighted Average Exercise Price Per Award Outstanding, Beginning Balance [3] $ 12.12    
Granted, Weighted Average Exercise Price Per Award [4] 7.76    
Forfeited/expired, Weighted Average Exercise Price Per Award [5] 16.54    
Weighted Average Exercise Price Per Award Outstanding, Ending Balance [3] 11.07 $ 12.12  
Exercisable, Weighted Average Exercise Price Per Award, Ending Balance [6] 15.05    
Weighted Average Exercise Price Per Award, Vested and expected to vest, Ending Balance [6] $ 12.15    
Weighted Average Remaining Contractual Term Outstanding [3] 7 years 7 years 1 month 6 days  
Exercisable Weighted Average Remaining Contractual Term [6] 6 years 7 months 6 days    
Weighted Average Remaining Contractual Term, Vested and expected to vest [6] 7 years 7 months 6 days    
Aggregate Intrinsic Value Outstanding [3],[7] $ 45.4 $ 0.0  
Exercisable, Aggregate Intrinsic Value [6],[7] 9.4    
Aggregate Intrinsic Value, Vested and expected to vest [6],[7] $ 28.4    
Granted, Weighted Average Grant Date Fair Value Per Share $ 4.17 $ 4.61 $ 7.83
[1] Includes 1.6 million performance-based restricted stock units as of December 31, 2025, which represents the maximum amount that can vest.
[2] Includes 1.3 million performance-based stock unit awards.
[3] Includes 3.9 million and 4.0 million performance condition SARs as of December 31, 2025 and 2024, respectively.
[4] Includes less than 0.1 million performance condition SARs.
[5] Includes 0.1 million performance condition SARs.
[6] Includes 0.5 million performance condition SARs.
[7] The intrinsic value is the amount by which the current market value of the underlying stock exceeds the exercise price of the stock awards.